Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028911 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01028911 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 9 participants.
The verdict
NCT01028911, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG PF-03654746
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028911
The ClinicalTrials.gov registry entry for NCT01028911 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01028911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028911 about?
NCT01028911 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease". This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.
What is the current status of trial NCT01028911?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2009-12. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01028911?
The interventions under investigation include: Placebo (DRUG), PF-03654746 (DRUG).
Who is sponsoring clinical trial NCT01028911?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.